Test Price
2,800 AED✅ Home Collection Available
CYP17A1 Genetic Sequencing (NGS) for 17α‑Hydroxylase Deficiency – Dubai, UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next‑generation sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (8 AM–11 PM daily across all Emirates).
- Clinical Guidance: Complimentary post‑test tele‑counselling with a DHA‑licensed clinical genetic counsellor.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This next‑generation sequencing (NGS) assay analyzes the entire coding region and splice junctions of the CYP17A1 gene to detect pathogenic variants causing 17α‑hydroxylase/17,20‑lyase deficiency – a rare autosomal recessive form of congenital adrenal hyperplasia. The assay provides comprehensive coverage for single‑nucleotide variants, small insertions/deletions, and copy number alterations.
| Feature | DNA Labs UAE – CYP17A1 NGS | Alternate Methods |
|---|---|---|
| Precision | Full‑gene NGS >99% analytical sensitivity & specificity | Targeted mutation panels with limited variant detection |
| Method | Illumina® NextSeq 550, paired‑end 150 bp, 100× mean depth | Sanger sequencing of selected exons (lower sensitivity for mosaicism) |
| Turnaround | 3–4 weeks from sample receipt | 4–6 weeks |
Physician Insight & Safety Protocols
“Genetic results for 17α‑hydroxylase deficiency must be integrated with biochemical profiles, adrenal imaging, and clinical history. This test supports informed family planning and individualized glucocorticoid management, but it does not replace a comprehensive endocrinology or genetics consultation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403)
Advisory Note: Medication Continuation
Do not discontinue prescribed corticosteroid or antihypertensive therapy without consulting your specialist. Abrupt withdrawal may precipitate a life‑threatening adrenal crisis. Always carry a medical alert card if on chronic glucocorticoid therapy.
Patient Exclusion Criteria & Emergency Red Flags
- Exclusion: Testing of minors without court‑approved parental consent and mandatory DHA‑regulated genetic counselling (per Federal Law No. 2 of 2019).
- Exclusion: Individuals who have received a red blood cell transfusion within the past 4 weeks (risk of DNA contamination).
- Exclusion: Inability to present a valid Emirates ID or passport for identity verification.
- Emergency Red Flags (seek immediate ER): Severe hyponatremia, life‑threatening hyperkalemia, hypotension unresponsive to fluids, altered consciousness, or clinical signs of acute adrenal insufficiency.
Patient FAQ & Clinical Guidance
1. What does the CYP17A1 genetic test diagnose?
Snippet: This test identifies mutations in the CYP17A1 gene that cause 17α‑hydroxylase deficiency, a rare congenital adrenal hyperplasia disrupting cortisol and sex steroid synthesis.
The NGS assay sequences all exons and splice junctions, detecting point mutations, small indels, and copy number variations with clinical‑grade accuracy. Positive results guide lifelong hormone replacement therapy and genetic counselling for family members.
2. How is the sample collected and when will I get the report?
Snippet: A single blood draw (whole blood) is collected at home by a DHA‑licensed phlebotomist using cold‑chain logistics, with results delivered in 3 to 4 weeks.
Our VIP mobile phlebotomy service operates daily from 8 AM to 11 PM across all Emirates. Alternately, an extracted DNA sample can be accepted. The report is securely uploaded to your patient portal and reviewed during a tele‑counselling session with a genetic counsellor.
3. Is this genetic test covered by UAE health insurance?
Snippet: Many UAE insurers cover diagnostic CYP17A1 sequencing when pre‑authorized; our team verifies your policy via WhatsApp for direct billing options.
We coordinate with major networks including Daman, AXA, Oman Insurance, and Nextcare. A valid medical reason (e.g., ambiguous genitalia, unexplained hypertension/hypokalemia) increases approval likelihood. Send your insurance card to +971 54 548 8731 for immediate eligibility confirmation.
UAE Regulatory & Data Privacy Adherence
This service strictly complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient genetic data is encrypted, access‑controlled, and processed under ISO 9001:2015 certification (INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | CYP17A1 Genetic Sequencing (NGS) for 17α‑Hydroxylase Deficiency |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA) – VIP mobile phlebotomy available |
| Methodology Used | Next‑Generation Sequencing (Illumina NextSeq 550, paired‑end 150 bp) |
| ICD-10-CM Code | E25.0 (Congenital adrenal hyperplasia, 17‑alpha‑hydroxylase deficiency) |
| LOINC Code | 21636-6 (CYP17A1 gene mutation analysis) |
| DHA Facility License & Laboratory Address | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DHA License No. 1143 |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians